OncoSec Medical Inc (NASDAQ: ONCS) is having an overwhelmingly strong day in the market today, and for good reason. The company released promising data with regard to the treatment of breast cancer. Today, we’ll talk about the data, what we’re seeing from the stock, and what we’ll be watching for ahead.
ONCS Gains On Encouraging Results
As mentioned above, OncoSec Medical is having an incredibly strong day in the market today after releasing preliminary clinical observations related to its pilot biomarker OMS-I1o40 clinical trial of ImmunoPulse® IL-12 in patients with metastatic Triple Negative Breast Cancer, also known as TNBC.
In the release issued earlier today, ONCS said that the study is designed to assess whether a single cycle of ImmunoPulse IL-12 increases TNBC tumor immunogenicity by driving a pro-inflammatory cascade of events. This includes activation of cytotoxic tumor-infiltrating lymphocytes.
In the release, ONCS said that five patients with TNBC have been treated with a single cycle of ImmunoPulse IL-12. In the release, the company announced that two of these five patients were subsequently treated with single agent nivolumab, as their immediate next therapy. The company said that both of these patients experienced robust objective responses in both ImmunoPulse IL-12 treated and untreated lesions. As a result, ONCS said that it has been prompted to further commit to a more definitive evaluation of the combined therapies. In a statement, Sharron Gargosky, Chief Clinical and Regulatory Officer at OncoSec, had the following to offer:
“Metastatic TNBC is a heterogeneous cancer with a poor prognosis where less than five percent of pre-treated patients achieve an objective response to PD-1/PD-L1 checkpoint treatments… The marked synergy shown in these patients strongly suggests that IL-12 may have primed the tumor microenvironment, impacting the clinical results. The combination of ImmunoPulse IL-12 and checkpoint inhibition represents a highly promising new therapeutic approach for TNBC and warrants a formal evaluation given the extremely low response rate in women who have failed multiple prior therapies.”
What We’re Seeing From The Stock
As investors, one of the first lessons that we learn when we start our work in the market is that the news causes the moves. In this particular case, the news released by ONCS proved to be overwhelmingly positive, leading to strong gains in the value of the stock. As is almost always the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (12:07), ONCS is trading at $2.08 per share after a gain of $0.24 per share or 12.70% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on ONCS. In particular, we’re interested in following the ongoing work surrounding ImmunoPulse and excited to hear more about the data in the future. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!